Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Japan, US, Europe Trade Groups Urge Ishiba Govt to Scrap Off-Year Revisions
November 18, 2024
-
BUSINESS MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
-
REGULATORY LDP Broadly OKs Draft Economic Package, Adds Text on FY2025 Revision
November 15, 2024
-
BUSINESS EMA Backs Leqembi after Re-Examination, but for Limited Use
November 15, 2024
-
REGULATORY MOF Stands Firm on Push for Full-Scale Off-Year Revision in FY2025
November 14, 2024
-
REGULATORY Kisunla Gets Reimbursement Listing with Daily NHI Price of 8,560 Yen
November 14, 2024
-
REGULATORY Japan Panel OKs Listing of Kisunla, Tepezza, Quviviq, and Many More
November 14, 2024
-
BUSINESS Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
-
REGULATORY DPP to Ruling Bloc: Quickly Scrap Off-Year Drug Price Revisions
November 13, 2024
-
ORGANIZATION Osaka’s New Life Science Hub to Grow into Full Ecosystem in 5 Years: Operator
November 12, 2024
-
BUSINESS Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief
November 12, 2024
-
REGULATORY Anapeine Generics Get Expedited Listing amid Supply Crunch
November 12, 2024
-
COMMENTARY With 1/4 of Pharma Backers Losing Seats, It’s Time for Industry to Revamp Lobbying Activities
November 11, 2024
-
REGULATORY MHLW Eyes Extra Budget for Pharma Innovation, Generic Rejig
November 11, 2024
-
BUSINESS Eisai Cuts Leqembi Sales Target as It Sees “Some Delays” in US Uptake
November 11, 2024
-
ACADEMIA Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
-
REGULATORY Chuikyo Supports Full Rollout of Company Indices for Generics Manufacturers
November 7, 2024
-
BUSINESS Nxera Pharma Eyes 50 Billion Yen in Global Revenue by 2030: CEO
November 7, 2024
-
ACADEMIA Alzheimer’s-Related Guidelines Being Revised to Accommodate Kisunla, Rexulti
November 6, 2024
-
ACADEMIA Japan Crafting Registry of All Hemophilia Patients, Company Use Eyed Too
November 5, 2024
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…